Home Page

SEATTLE, March 30, 2015 /PRNewswire/ -- TapImmune Inc. (OTCQB: TPIV), wishes to provide clarification on its participation at the Fifth Annual "Cancer Immunotherapy: A Long-Awaited Reality" conference at the New York Academy of Medicine in New York City on March 26.  TapImmune was represented at this meeting by Dr. Glynn Wilson, Chairman & CEO of TapImmune and Dr. John Bonfiglio, Strategic Advisor to the Company.  Regrettably, due to parallel meeting sessions running behind schedule, Dr. Wilson was unable to present a webcast at 4:30pm Eastern Time as originally scheduled in order to participate as an invited panellist in an important discussion on "What is the Role of Cancer Vaccines in an Environment Overwhelmed by Checkpoint Inhibitors and T Cell Immunotherapies?"  Other panellists were Dr. Robert Stein, CSO of Agenus, Inc., Dr. Reiner Laus, CEO of Annias Immunotherapeutics, Dr. Robert Pierce, CMO of OncoSec Medical, and David Berd, CMO of AVAX Technologies.  The panel discussion was moderated by Dr. Mac Cheever, MD, Fred Hutchinson Cancer Research Center, who also served as the Keynote speaker at the conference.

TapImmune regrets any inconvenience to those who wished to hear the webcast; however, the circumstances were beyond our control. The Company has put the Maidstone presentation on its website at www.tapimmune.com.

Dr Glynn Wilson stated, "On a most positive note, the meeting was focussed around the latest immunotherapies in development and the future of cancer treatments. It was clear from the presentations and the comments of the key opinion leaders attending the meeting that the T-cell therapies of TapImmune are currently developing fit into the combination strategies believed to be the future of treatment regimens."

About TapImmune Inc.

TapImmune Inc. is an immunotherapy company specializing in the development of innovative technologies for the treatment of cancer, including metastasis, and infectious disease. The Company's peptide or nucleic acid-based immunotherapeutics, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patients' killer T-cells, helper T-cells and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. The Company's technologies may be used as stand-alone medications or in combination with current treatment modalities. Please visit the Company's website at www.tapimmune.com for details. 

Forward-Looking Statement Disclaimer 
This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements". Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company's most recent Form 10-K and other SEC filings which are available through EDGAR at www.sec.gov. The Company assumes no obligation to update the forward-looking statements.

CONTACTS:

TapImmune Inc.,
Glynn Wilson, Ph.D.
Chairman & CEO
(866)-359-7541

PCG Advisory
Kirin M. Smith
Chief Operating Officer
(646)-863-6519

Sean Leous
Chief Communications Officer
(646) 863-8998
www.pcgadvisory.com

J. Streicher Capital, LLC
Robert Giordano
917-327-3938

SOURCE TapImmune Inc.